Investigational J-valve system shows favorable 1-year outcomes for severe aortic regurgitation

by Society for Cardiovascular Angiography and Interventions

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

New research published in JSCAI and presented at New York Valves 2026 reports favorable one-year outcomes in patients with symptomatic severe aortic regurgitation following treatment with the investigational J-Valve Transfemoral System.

The study, "Transcatheter Aortic Valve Replacement in Patients with Symptomatic, Severe Aortic Regurgitation: One-Year Outcomes of the J-Valve Transfemoral Early Feasibility Study," evaluated the safety and effectiveness of the transfemoral J-Valve transcatheter heart valve system in patients with severe native aortic regurgitation who were deemed high risk for surgical aortic valve replacement.

Aortic regurgitation occurs when the aortic valve does not close properly, allowing blood to leak backward into the heart. Surgical aortic valve replacement remains the guideline-recommended therapy for many patients with severe AR, but treatment options are limited for patients who are older or have other factors that make surgery more complex.

"Severe native aortic regurgitation is a difficult disease to treat with transcatheter therapy. However, this early feasibility study for J-Valve is encouraging because it shows that a dedicated device designed for AR can achieve sustained valve performance, meaningful symptom improvement and evidence of reverse left ventricular remodeling at one year," said first author Dean J. Kereiakes, MD, MSCAI, chair of the Christ Hospital Heart and Vascular Institute in Cincinnati.

"While larger studies are needed, these data support continued evaluation of the J-Valve system as a potential option for patients with severe AR and limited alternatives."

The prospective, single-arm, multicenter early feasibility study enrolled 25 patients at eight U.S. centers. Participants had a mean age of 80.6 years, all had symptomatic severe native AR and all were deemed high risk for surgical aortic valve replacement by a local multidisciplinary Heart Team.

Successful valve implantation occurred in 92% of patients. The primary endpoint, a composite of all-cause mortality or disabling stroke at 30 days, occurred in two patients (8.0%). All-cause mortality was 4.0% at 30 days and at one year, with no cardiovascular-related deaths.

Patients experienced sustained improvements in symptoms and health status. At one year, New York Heart Association functional class improved in 72.7% of patients, with 95.5% in Class I or II. Reverse left ventricular remodeling was evident at 30 days and sustained through one year. Continued follow-up through five years is planned, and more definitive evidence is expected from the larger ongoing JOURNEY trial.

More information

Transcatheter Aortic Valve Replacement in Patients with Symptomatic, Severe Aortic Regurgitation: One-Year Outcomes of the J-Valve Transfemoral Early Feasibility Study, JSCAI (2026). DOI: 10.1016/j.jscai.2026.105509

Key medical concepts

Aortic Valve InsufficiencyTranscatheter Aortic Valve ReplacementAortic Valve

Clinical categories

Cardiology Provided by Society for Cardiovascular Angiography and Interventions Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Investigational J-valve system shows favorable 1-year outcomes for severe aortic regurgitation (2026, June 25) retrieved 25 June 2026 from https://medicalxpress.com/news/2026-06-valve-favorable-year-outcomes-severe.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.